Brind.

Incannex Healthcare Inc. is developing IHL-42X for Obstructive Sleep Apnoea (OSA) treatment, showing significant efficacy.

3 reports, 2 independent Updated Aug 25
Gone quiet
Reports
3
Developments
3
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Incannex Healthcare Inc. is developing IHL-42X for Obstructive Sleep Apnoea (OSA) treatment, showing significant efficacy.

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA granted Fast Track designation for IHL-42X developed by Incannex Healthcare for OSA.1 source
  2. Kirsch joins the advisory board to support the advancement of IHL-42X for Obstructive Sleep Apnoea (OSA) treatment.Sub-event
  3. IHL-42X, developed by Incannex, showed up to 83% reduction in OSA severity.1 source

Coverage

Newest first; wire copies grouped
  • sleepreviewmag.comParticipant Screening Begins for Phase 2 Study of Novel OSA Therapy
  • GlobeNewswireIncannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X Statistically and clinically significant improvements across key clinical endpoints; IHL-42X reduced AHI by up to 83% fr
1 more outlet ran the same wire story